This large, prospective population-based study from Iceland investigated whether SARS-CoV-2 vaccination affects M protein trajectories in over 1,800 individuals with MGUS or smoldering multiple myeloma (SMM). Using linear mixed-effects models with patient-specific trajectories, flexible spline-based age modelling, and standardised marginal comparisons, the study found that annual increases in M protein levels were small and similar before and after vaccination – across sexes, isotypes, vaccine types, and dose numbers. These findings provide reassurance that SARS-CoV-2 vaccines do not adversely affect M protein dynamics in individuals with MGUS and SMM.
Publication details
Palmason R, Eythorsson E, Rögnvaldsson S, Thorsteinsdóttir S, Ekberg S, Crowther M, Reed ER, Oskarsson J Þ, Sigurdardottir GA, Aspelund T, Vidarsson B, Onundarson PT, Agnarsson BA, Sigurdardottir M, Thorsteinsdottir I, Sveinsdottir SV, Olafsson I, Thordardottir AR, Jonsson A, Indridason OS, Gislason G, Olafsson A, Sigurdsson JK, Steingrimsdottir H, Long TE, Hultcrantz M, Durie BGM, Harding S, Landgren O, Palsson R, Love TJ, Kristinsson SY. Impact of SARS-CoV-2 vaccination on monoclonal gammopathy of undetermined significance: results from the population-based iStopMM study. Blood Cancer Journal 2026.